Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS
New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD
SALT LAKE CITY, Utah, Nov. 28, 2016 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 6-10, 2016 in San Antonio, Texas.
“Myriad Genetics is proud to offer the highest-quality molecular diagnostic tests designed to help prevent breast cancer and improve health outcomes for those with breast cancer,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “We’re excited to present six new studies at SABCS this year, including data on: EndoPredict®, a second-generation test that predicts the risk of recurrence; myRisk™ Hereditary Cancer, the gold standard test to identify people at risk for hereditary breast cancer; and myChoice® HRD, an innovative novel companion diagnostic test to identify optimal pharmaceutical decisions for patients.”
A list of the Myriad presentations at SABCS is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS16.
EndoPredict® Presentation
• Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak.
Date: Friday, Dec.9, 2016: 4:15 p.m. CT.
Location: S6-05; General Session 6 - Hall 3.
myRisk™ Hereditary Cancer Presentations
• Title: Genetic testing for Hereditary Breast and Ovarian Cancer Syndrome among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance. Presenter: Paul Baron.
Date: Thursday, Dec. 8, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P3-10-06.
• Title: Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk.
Presenter: Heidi Gorringe.
Date: Thursday, Dec. 8, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P3-08-04.
myChoice® HRD Presentations
• Title: Homologous repair deficiency (HRD) as a measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer.
Presenter: Gunter von Minckwitz.
Date: Wednesday, Dec.7, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P1-09-02.
• Title: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).
Presenter: Andrew Tutt.
Date: Friday, Dec.9, 2016: 3:15 p.m. CT.
Location:S6-01; General Session 6 - Hall 3.
• Title: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis. Presenter: Melinda Telli.
Date: Saturday, Dec.10, 2016: 7:30 - 9:00 a.m. CT.
Location: Poster P6-09-09.
For more information about these presentations, please visit the SABCS website at https://www.sabcs.org/.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: https://www.myriad.com/.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
SALT LAKE CITY, Utah, Nov. 28, 2016 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 6-10, 2016 in San Antonio, Texas.
“Myriad Genetics is proud to offer the highest-quality molecular diagnostic tests designed to help prevent breast cancer and improve health outcomes for those with breast cancer,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “We’re excited to present six new studies at SABCS this year, including data on: EndoPredict®, a second-generation test that predicts the risk of recurrence; myRisk™ Hereditary Cancer, the gold standard test to identify people at risk for hereditary breast cancer; and myChoice® HRD, an innovative novel companion diagnostic test to identify optimal pharmaceutical decisions for patients.”
A list of the Myriad presentations at SABCS is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS16.
EndoPredict® Presentation
• Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak.
Date: Friday, Dec.9, 2016: 4:15 p.m. CT.
Location: S6-05; General Session 6 - Hall 3.
myRisk™ Hereditary Cancer Presentations
• Title: Genetic testing for Hereditary Breast and Ovarian Cancer Syndrome among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance. Presenter: Paul Baron.
Date: Thursday, Dec. 8, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P3-10-06.
• Title: Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk.
Presenter: Heidi Gorringe.
Date: Thursday, Dec. 8, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P3-08-04.
myChoice® HRD Presentations
• Title: Homologous repair deficiency (HRD) as a measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer.
Presenter: Gunter von Minckwitz.
Date: Wednesday, Dec.7, 2016: 5:00 - 7:00 p.m. CT.
Location: Poster P1-09-02.
• Title: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012).
Presenter: Andrew Tutt.
Date: Friday, Dec.9, 2016: 3:15 p.m. CT.
Location:S6-01; General Session 6 - Hall 3.
• Title: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis. Presenter: Melinda Telli.
Date: Saturday, Dec.10, 2016: 7:30 - 9:00 a.m. CT.
Location: Poster P6-09-09.
For more information about these presentations, please visit the SABCS website at https://www.sabcs.org/.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: https://www.myriad.com/.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G